Track topics on Twitter Track topics that are important to you
Nasal Ketamine has previously been tested in children for deep sedation or preoperative anxiolysis. The investigators intend to test the efficacy of low dose nasal Ketamine in children undergoing minor procedures in the emergency department.
The investigators propose a feasibility study of intranasal ketamine to provide analgesia and anxiolysis before minor procedures. This will be a single-blinded randomized study of inhaled ketamine in a convenience sample of children ages 4-12 years of age undergoing minor procedures. For the purpose of this study, the investigators will limit minor procedures to venipuncture and IV placement, and will further limit the patient population to children who are deemed by the investigators to show resistance to IV placement or venipuncture without premedication. The investigators have chosen the ages 4-12 years because these children are verbal and able to rate their pain on the VAS scales, because they are likely to require restraint and to require a staff member to assist parents with restraint, and because the Green study found this age range to have the fewest adverse events with ketamine.
The investigators propose a uniform dosing of 50 mg/ml intranasal ketamine at 1 mg/kg. Ketamine will be diluted to achieve volumes between 0.5-1 ml distributed between nares. The plasma concentration of intranasal ketamine is just over a fifth of IV ketamine, and the peak serum concentration is reached an average of fifteen minutes later than IV ketamine. Thus, intranasal administration found to have achieved mild sedation at 1 mg/kg would be expected to achieve a lower level of sedation than a 0.2 mg/kg slow IV administration, which is compatible with subdissociative dosing used for analgesia. A 1 mg/kg intranasal dose is also consistent with the lower end of the dosing spectrum used in the anesthesia literature for preoperative sedation.
The investigators propose a pilot study of 20 children ages 4-12 years undergoing venipuncture or IV insertion. After obtaining informed consent from a single parent (the investigators request exclusion from requiring consent from both parents), the children will be assigned to receive 1 mg/kg intranasal ketamine via atomizer. Consent will occur after the treating physician has decided that the child requires bloodwork or IV placement, and will not impact this decision.
All children will receive EMLA. EMLA cream is the standard of care in our area and we feel that it would not be ethical to withhold EMLA for the purpose of the study. Ketamine will add to the incomplete analgesia of EMLA, and may be a better option than EMLA in children who are known to have difficult venous access. EMLA is not universally effective -- having been found to decrease VAS pain scores by only 61%-- and causes vasoconstriction, which can increase the procedural fail rate.
Ketamine will be administered 30 minutes after EMLA is applied. At or about the 45 minute mark, the procedure will be attempted.
All children will receive continuous monitoring of pulse oximetry, blood pressure and pulse rate from the time medication is administered until the child is discharged from the emergency department. All children will be under the direct and continuous observation of ED staff. The procedure will be completed within twenty minutes of the completion of the nasal administration.
After the procedure is completed, children will be asked to rate the level of procedural pain on the Faces scale. A parent and the nurse at the procedure will rate the estimated procedural pain on the VAS scale. Child, parent as nurse will be blinded to each other's score.
The investigators intend to show that nasal ketamine requires a minimal disruption in ED resources and treatment time, effectively treats pain and increases the child's compliance with venipuncture and IV placement, increases parent satisfaction, and is without serious adverse events.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intranasal ketamine, Intranasal atomizer, EMLA
Not yet recruiting
Kaplan Medical Center
Published on BioPortfolio: 2016-07-22T02:53:22-0400
The general objective of this study is to determine whether intranasal ketamine should be incorporated into formulary as an option to treat pain during minor procedures in the pediatric em...
This is an open label, single-center study to determine whether certain nasal medication interact with PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers and in patients with ...
This study compares the analgesic effect of intranasal sub-dissociative dosing of ketamine and intranasal fentanyl in children presenting to the Emergency Department with acute extremity i...
The purpose of this research study is to evaluate the safety and analgesic efficacy of PMI-150 (intranasal ketamine) compared to placebo in patients with acute post-operative pain followin...
We are attempting to determine if ketamine can offer rapid, complete and sustained headache relief in the acute setting and 48 hrs post-discharge. The goal of this study is to enroll 40 pa...
Timely analgesia is critical for children with injuries presenting to the emergency department, yet pain control efforts are often inadequate. Intranasal administration of pain medications provides ra...
This study aimed to compare analgesic efficacy of intranasal (IN) ketamine to IN fentanyl for moderate to severe pain in children in a pediatric emergency department.
Intranasal lidocaine has been studied and recommended as an alternative in the management of acute headache. The objective of this systematic review was to evaluate the efficacy and safety of intranas...
The intranasal route of administration allows large therapeutics to circumvent the blood-brain barrier and be delivered directly to the CNS. Here we examined the distribution and pattern of cellular t...
Previous studies reveal that oxytocin (OT) encourages prosocial behavior in humans; however, animal studies and recent work in humans suggest that OT may also play a role in aggressive behavior and fe...
The administration of drugs through the nasal passage.
A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.
A type of pain that is perceived in an area away from the site where the pain arises, such as facial pain caused by lesion of the VAGUS NERVE, or throat problem generating referred pain in the ear.
Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...